Trial Profile
A phase I trial of AVN-944 in patients with advanced hematologic malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs AVN 944 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Avalon Pharmaceuticals
- 02 Aug 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.
- 09 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2008 The company is on track to complete this trial in 2008.